Novo CEO insists ‘no change in plan’ for CagriSema launch after single-chamber device ditched

Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending work on a single-cham...